Aldoss I, La Rosa C, Baden LR, et al. Poxvirus Vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med 2020; 172: 306–316.

Aldoss I, La Rosa C, Baden LR, et al. Poxvirus Vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med 2020; 172: 306–316.)| false
• Search Google Scholar
• Export Citation

Basar R, Daher M, Uprety N. Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells 2020; 4: 3357–3367.

Basar R, Daher M, Uprety N. Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells 2020; 4: 3357–3367.)| false
• Search Google Scholar
• Export Citation

Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis 2021; 13: 123–140.

Jakharia N, Howard D, Riedel DJ. CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies. Curr Treat Options Infect Dis 2021; 13: 123–140.)| false
• Search Google Scholar
• Export Citation

Ljungman P, Bermudez A, Logan AC, et al. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine 2021; 33: 100787.

Ljungman P, Bermudez A, Logan AC, et al. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine 2021; 33: 100787.)| false
• Search Google Scholar
• Export Citation

Marty FM, Ljungman P, Chemaly RF. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017; 377: 2433-2444.

Marty FM, Ljungman P, Chemaly RF. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017; 377: 2433-2444.)| false
• Search Google Scholar
• Export Citation

Papadopoulou A, Alvanou M, Karavalakis G, et al. Pathogen-specific T cells: targeting old enemies and new invaders in transplantation and beyond. HemaSphere 2023; 7: 1(e809).

Papadopoulou A, Alvanou M, Karavalakis G, et al. Pathogen-specific T cells: targeting old enemies and new invaders in transplantation and beyond. HemaSphere 2023; 7: 1(e809).)| false
• Search Google Scholar
• Export Citation

Pérez-Martínez A, Mora-Rillo M, Ferreras C, et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 2021; 39: 101086.

Pérez-Martínez A, Mora-Rillo M, Ferreras C, et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 2021; 39: 101086.)| false
• Search Google Scholar
• Export Citation

Rashidi A, La Rosa C, Curtsinger J, et al. CMV Triplex vaccine to enhance adaptive NK and Tcell reconstitution after autologous hematopoietic cell transplantation. Transpl Cell Ther 2022; 28: 343.e1–343.e4.

Rashidi A, La Rosa C, Curtsinger J, et al. CMV Triplex vaccine to enhance adaptive NK and Tcell reconstitution after autologous hematopoietic cell transplantation. Transpl Cell Ther 2022; 28: 343.e1–343.e4.)| false
• Search Google Scholar
• Export Citation

Schmidt-Hieber M, Tridello G, Ljungman P, et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol 2019; 98: 1755–1763.

Schmidt-Hieber M, Tridello G, Ljungman P, et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol 2019; 98: 1755–1763.)| false
• Search Google Scholar
• Export Citation

Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther 2018; 7: 1–16.

Styczynski J. Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation. Infect Dis Ther 2018; 7: 1–16.)| false
• Search Google Scholar
• Export Citation

Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep 2018; 20: 4.

Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep 2018; 20: 4.)| false
• Search Google Scholar
• Export Citation

Wagner-Drouet E, Teschner D, Wolschke C, et al. Standardized monitoring of cytomegalovirusspecific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Hematologica; 2021; 106: 363–374.

Wagner-Drouet E, Teschner D, Wolschke C, et al. Standardized monitoring of cytomegalovirusspecific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Hematologica; 2021; 106: 363–374.)| false
• Search Google Scholar
• Export Citation